Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists is the mainstay of treatment for metastatic prostate cancer (mCaP). However, ADT is associated with serious cardiovascular events.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Only a few studies that directly compare the cardiovascular risk of LHRH agonists versus GnRH antagonists have been published.
This review aims to compare the cardiovascular risk of LHRH agonists versus GnRH antagonists based on the literature.
A literature search that considered full publications and abstracts published before December 10, 2014 was performed. Due to their high evidence quality, only meta-analyses and pooled studies were included in this review.
Four studies were included. These investigated the cardiovascular risk of patients receiving an ADT with LHRH agonists and/or GnRH antagonists. However, only one of these directly compared the cardiovascular risk of ADT with LHRH agonists versus GnRH antagonists. This meta-analysis showed a significant reduction in cardiovascular risk for patients receiving a GnRH antagonist compared to those patients receiving a LHRH agonist (HR: 0. 597; 95 % CI: 0. 380-0. 938; P = 0. 0253). Subgroup analyses showed that, in particular, patients with pre-existing cardiovascular diseases who were treated with a GnRH antagonist have a significantly lower risk of experiencing a cardiovascular event when compared with patients receiving a GnRH agonist (HR: 0. 44; 95 % CI: 0. 26-0. 74; P = 0. 002).
In conclusion, GnRH antagonists are associated with a lower risk of cardiovascular events, compared with LHRH agonists, when administered as ADT in CaP patients, and particularly in patients with a history of cardiovascular disease. Thus, patients with a history of cardiovascular disease may benefit from ADT with a GnRH antagonist.
Der Urologe. Ausg. A. 2015 Dec 04 [Epub ahead of print]
Axel S Merseburger, Daniel Sedding, Kai Hüter
Klinik und Poliklinik für Urologie, Akkreditiertes Zweitmeinungszentrum Keimzelltumoren, Zertifiziertes Kontinenz- und Beckenboden-Zentrum, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 60, 23538, Lübeck, Deutschland. Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover (MHH), Hannover, Deutschland. , Urologie am Nordkopf, Wolfsburg, Deutschland.